Advanced SearchSearch Tips
Roles of Ki67 in Breast Cancer - Important for Management?
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Roles of Ki67 in Breast Cancer - Important for Management?
Yip, CH; Bhoo-Pathy, N; Daniel, JM; Foo, YC; Mohamed, AK; Abdullah, MM; Ng, YS; Yap, BK; Pathmanathan, R;
  PDF(new window)
Background: The three standard biomarkers used in breast cancer are the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). The Ki-67 index, a proliferative marker, has been shown to be associated with a poorer outcome, and despite absence of standardization of pathological assessment, is widely used for therapy decision making. We aim to study the role of the Ki-67 index in a group of Asian women with breast cancer. Materials and Methods: A total of 450 women newly diagnosed with Stage 1 to 3 invasive breast cancer in a single centre from July 2013 to Dec 2014 were included in this study. Univariable and multivariable logistic regression was used to determine the association between Ki-67 (positive defined as 14% and above) and age, ethnicity, grade, mitotic index, ER, PR, HER2, lymph node status and size. All analyses were performed using SPSS Version 22. Results: In univariable analysis, Ki -67 index was associated with younger age, higher grade, ER and PR negativity, HER2 positivity, high mitotic index and positive lymph nodes. However on multivariable analysis only tumour size, grade, PR and HER2 remained significant. Out of 102 stage 1 patients who had ER positive/PR positive/HER2 negative tumours and non-grade 3, only 5 (4.9%) had a positive Ki-67 index and may have been offered chemotherapy. However, it is interesting to note that none of these patients received chemotherapy. Conclusions: Information on Ki67 would have potentially changed management in an insignificant proportion of patients with stage 1 breast cancer.
Ki-67 index;invasive breast cancer;indications for chemotherapy;
 Cited by
Malaysian Clinical Practice Guidelines for the Management of Breast Cancer Nov 2010

Andre F, Arnedos M, Goubar A, et al (2015). Ki67-no evidence for its use in node-positive breast cancer. Nat Rev Clin Oncol.

Cheang MC, Chia SK, Voduc D, et al (2009). Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst, 101, 736-50. crossref(new window)

Cuzick J, Dowsett M, Pineda S, et al (2011). Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol, 29, 4273-8. crossref(new window)

de Azambuja E, Cardoso F, de Castro G, Jr., et al (2007). Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer, 96, 1504-13. crossref(new window)

Dowsett M, Nielsen TO, A'Hern R, et al (2011). Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst, 103, 1656-64. crossref(new window)

Dowsett M, Smith IE, Ebbs SR, et al (2007). Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst, 99, 167-70. crossref(new window)

Goldhirsch A, Winer EP, Coates AS, et al (2013). Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol, 24, 2206-23. crossref(new window)

Goldhirsch A, Wood WC, Coates AS, et al (2011). Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the st. gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol, 22, 1736-47. crossref(new window)

Hammond ME, Hayes DF, Dowsett M, et al (2010). American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol, 28, 2784-95. crossref(new window)

Inwald EC, Klinkhammer-Schalke M, Hofstadter F, et al (2013). Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat, 139, 539-52. crossref(new window)

Jonat W, Arnold N (2011). Is the Ki-67 labelling index ready for clinical use? Ann Oncol, 22, 500-2. crossref(new window)

Keam B, Im SA, Lee KH, et al (2011). Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res, 13, 22.

Nishimura R, Osako T, Okumura Y, et al (2010). Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis. Breast Cancer, 17, 269-75. crossref(new window)

Spyratos F, Ferrero-Pous M, Trassard M, et al (2002). Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value. Cancer, 94, 2151-9. crossref(new window)

Trihia H, Murray S, Price K, et al (2003). Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors--a surrogate marker? Cancer, 97, 1321-31. crossref(new window)

Urruticoechea A, Smith IE, Dowsett M (2005). Proliferation marker Ki-67 in early breast cancer. J Clin Oncol, 23, 7212-20. crossref(new window)

Wiesner FG, Magener A, Fasching PA, et al (2009). Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients. Breast, 18, 135-41. crossref(new window)

Wishart GC, Azzato EM, Greenberg DC, et al (2010). PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res, 12, R1. crossref(new window)

Wolff AC, Hammond ME, Hicks DG, et al (2014). Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline update. Arch Pathol Lab Med, 138, 241-56. crossref(new window)